Whether TET2 participates in immune checkpoint suppression mediated by the CTLA-4 or PD-1 pathway, whether and how TET2 acts on CD8+ cytotoxic T lymphocytes, and coordination of PD-L1/CTLA-4 to regulate the anti-cancer CD8+ T-cell response remain to be studied further. The gene discussed is CD8A; the disease is cancer.